13th Annual ADMET conference by SMi Group
In-Person Event
Jul 09 - 10, 2018
London, England, GB
OVERVIEW
13th Annual ADMET conference is organized by SMi Group and will be held from Jul 09 - 10, 2018 at Holiday Inn London - Kensington Forum, London, England, United Kingdom.
The target audience for this medical event is DMPK Professionals, Pharmacologists, Computational Scientists, Medicinal Chemists, Statisticians, Principle scientist, Drug Metabolism Experts, ADME Toxicologists, Research fellows, PK/PD modeling Toxicologist, Anatomists. This event is CPD accredited.
Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.
The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.
Join our expert speaker panels at the ADMET conference to ensure you do not miss out on the latest developments! Presenting new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and many more.
The ADMET conference will cover new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling techniques to the validation of humanised mice models.
Join us this year in July to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:
• ADME/PK Optimisation for Drug Design and Discovery
• Physiochemical Assessments
• Drug Screening Technology
• In Vitro to Human In Vivo Translation
• DMPK, PBPK and PKPD Modelling
• Pre-/Clinical Toxicity
• Biopharmaceuticals
• Accurate First-in-Human Dose Predictions
• Transporters, Bioavailability, Formulation
• Metabolism Studies
• Drug-Drug Interactions
Prices:
Conference Only: GBP 1499,
Distribution of your company's promotional literature to all conference attendees: GBP 999,
Access to the conference documentation on the Document Portal: GBP 499,
The Conference Presentations - paper copy: GBP 499
Speakers: Eric Bloome, Pau Aceves, Peter Littlewood, Filipe Lopes, Andreas Reichel, Laurent Salphati, Timothy Schulz-Utermoehl, Kunal Taskar, Robert Van Waterschoot, Ian Wilson
Additional details will be posted as soon as they are available.
The target audience for this medical event is DMPK Professionals, Pharmacologists, Computational Scientists, Medicinal Chemists, Statisticians, Principle scientist, Drug Metabolism Experts, ADME Toxicologists, Research fellows, PK/PD modeling Toxicologist, Anatomists. This event is CPD accredited.
Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost, and minimise production times.
The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.
Join our expert speaker panels at the ADMET conference to ensure you do not miss out on the latest developments! Presenting new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and many more.
The ADMET conference will cover new developments in all areas of the ADMET sector, from the evaluation of novel PBPK modelling techniques to the validation of humanised mice models.
Join us this year in July to hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:
• ADME/PK Optimisation for Drug Design and Discovery
• Physiochemical Assessments
• Drug Screening Technology
• In Vitro to Human In Vivo Translation
• DMPK, PBPK and PKPD Modelling
• Pre-/Clinical Toxicity
• Biopharmaceuticals
• Accurate First-in-Human Dose Predictions
• Transporters, Bioavailability, Formulation
• Metabolism Studies
• Drug-Drug Interactions
Prices:
Conference Only: GBP 1499,
Distribution of your company's promotional literature to all conference attendees: GBP 999,
Access to the conference documentation on the Document Portal: GBP 499,
The Conference Presentations - paper copy: GBP 499
Speakers: Eric Bloome, Pau Aceves, Peter Littlewood, Filipe Lopes, Andreas Reichel, Laurent Salphati, Timothy Schulz-Utermoehl, Kunal Taskar, Robert Van Waterschoot, Ian Wilson
Additional details will be posted as soon as they are available.
KEY DATES
09 Jul, 2018
Event Start Date
10 Jul, 2018
Event End Date
SPECIALITIES
ToxicologyPharmacy and MedicineSUGGESTED HOTELS
CONFERENCE VENUE
Holiday Inn London - Kensington ForumQuick Links